Benzinga··Vandana SinghLigand Pharmaceuticals Acquires XOMA for $739M to Expand Royalty Portfolio
Ligand Pharmaceuticals acquires XOMA Royalty for $739M, immediately accretive to EPS with 2026 guidance raised to $8.50–$9.50 per share.
LGNDXOMAXOMAOXOMAPacquisitionM&A